Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 166
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Clin Exp Immunol ; 183(1): 1-7, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25989477

RESUMEN

Type 1 diabetes (T1D) is one of the most common and severe chronic diseases affecting both children and adults. The aetiology of the disease remains unknown, and thus far no 'true' cure for those affected is available. Indeed, exogenous insulin replacement therapy to manage glucose metabolism to the best degree possible remains the current standard of care. However, despite a recent array of truly impressive improvements designed to enhance disease management (e.g. insulin analogues, continuous glucose monitoring, insulin pumps), it is still difficult for the vast majority of patients to reach recommended target HbA1C levels (< 7.0%). As a result of suboptimal disease management, far too many patients with T1D have an increased risk for disease-associated complications such as nephropathy, neuropathy and retinopathy, as well as hypoglycaemia. New treatment modalities are therefore needed urgently to bring a 'true' cure (disease prevention/disease reversal) to patients with T1D. Here we consider issues that collectively pose a major stumbling block in T1D research with respect to identifying a means to prevent and/or cure the disease. We begin this Perspective by discussing new insights emanating from studies of the pancreas in human T1D; findings which may, at least in part, explain why previous interventions seeking disease prevention/reversal have yielded insufficient benefit. We then turn to suggestions that could optimise the outcome of future clinical trials. Finally, we direct attention to recommendations for the global T1D research community; messages we deem to have the potential to improve our chances of finding the elusive T1D 'cure'.


Asunto(s)
Glucemia/metabolismo , Diabetes Mellitus Tipo 1/terapia , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Páncreas/metabolismo , Adulto , Animales , Niño , Humanos , Páncreas/patología , Investigación Biomédica Traslacional
2.
Clin Exp Immunol ; 182(3): 278-88, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26313035

RESUMEN

In this study we aim to describe the characteristics of non-diabetic organ donors with circulating diabetes-associated autoantibodies collected within the Nordic Network for Islet Transplantation. One thousand and thirty organ donors have been screened in Uppsala for antibodies against glutamic acid decarboxylase (GADA) and islet antigen-2 (IA-2A). The 32 non-diabetic donors that tested positive for GADA (3.3% of all non-diabetic donors) were studied in more detail, together with 32 matched controls. Mean age among the autoantibody-positive donors was 52.6 (range 21-74), family history of type 1 diabetes (T1D) was unknown, and no donor was genetically predisposed for T1D regarding the human leucocyte antigen (HLA) locus. Subjects were analysed for islet cell antibodies (ICA), insulin autoantibodies (IAA) and zinc transporter 8 antibodies (ZnT8A), and pancreas morphology and clinical data were examined. Eight non-diabetic donors tested positive for two antibodies and one donor tested positive for four antibodies. No insulitis or other signs of a diabetic process were found in any of the donors. While inflammatory cells were present in all donors, subjects with high GADA titres had significantly higher CD45 cell numbers in exocrine tissue than controls. The extent of fibrosis was more pronounced in autoantibody-positive donors, even in subjects with lower GADA titres. Notably, it is possible that events not related directly to T1D (e.g. subclinical pancreatitis) may induce autoantibodies in some cases.


Asunto(s)
Autoanticuerpos/sangre , Diabetes Mellitus Tipo 1 , Selección de Donante/métodos , Trasplante de Islotes Pancreáticos , Donantes de Tejidos , Autoanticuerpos/inmunología , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/cirugía , Femenino , Glutamato Descarboxilasa/inmunología , Humanos , Masculino , Proteínas Tirosina Fosfatasas Clase 8 Similares a Receptores/inmunología
3.
Am J Transplant ; 14(3): 694-700, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24517268

RESUMEN

Insulin-producing cells are transplanted by portal vein injection as an alternative to pancreas transplantation in both clinical and preclinical trials. Two of the main limitations of portal vein transplantation are the prompt activation of the innate immunity and concomitant loss of islets and a small but significant risk of portal vein thrombosis. Furthermore, to mimic physiological release, the insulin-producing cells should instead be located in the pancreas. The trans-vessel wall approach is an endovascular method for penetrating the vessel wall from the inside. In essence, a working channel is established to the parenchyma of organs that are difficult to access by percutaneous technique. In this experiment, we accessed the extra-vascular pancreatic parenchyma in swine by microendovascular technique and injected methylene blue, contrast fluids and insulin-producing cells without acute adverse events. Further, we evaluated the procedure itself by a 1-year angiographical follow-up, without adverse events. This study shows that the novel approach utilizing endovascular minimal invasiveness coupled to accurate trans-vessel wall placement of an injection in the pancreatic parenchyma with insulin-producing cells is possible. In clinical practice, the potential benefits compared to portal vein cell transplantation should significantly improve endocrine function of the graft and potentially reduce adverse events.


Asunto(s)
Procedimientos Endovasculares/métodos , Supervivencia de Injerto/fisiología , Insulina/metabolismo , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos/citología , Páncreas/cirugía , Angiografía , Animales , Glucemia/análisis , Péptido C/metabolismo , Técnicas para Inmunoenzimas , Secreción de Insulina , Páncreas/diagnóstico por imagen , Páncreas/patología , Porcinos
4.
Clin Exp Immunol ; 173(2): 310-22, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23607776

RESUMEN

Adoptive transfer of regulatory T cells (T(regs)) has been proposed for use as a cellular therapy to induce transplantation tolerance. Preclinical data are encouraging, and clinical trials with T(reg) therapy are anticipated. In this study, we investigate different strategies for the isolation and expansion of CD4(+) CD25(high) CD127(low) T(regs) from uraemic patients. We use allogeneic dendritic cells (DCs) as feeder cells for the expansion and compare T(reg) preparations isolated by either fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS) that have been expanded subsequently with either mature or tolerogenic DCs. Expanded T(reg) preparations have been characterized by their purity, cytokine production and in-vitro suppressive ability. The results show that T(reg) preparations can be isolated from uraemic patients by both FACS and MACS. Also, the type of feeder cells used in the expansion affects both the purity and the functional properties of the T(reg) preparations. In particular, FACS-sorted T(reg) preparations expanded with mature DCs secrete more interleukin (IL)-10 and granzyme B than FACS-sorted T(reg) preparations expanded with tolerogenic DCs. This is a direct comparison between different isolation techniques and expansion protocols with T(regs) from uraemic patients that may guide future efforts to produce clinical-grade T(regs) for use in kidney transplantation.


Asunto(s)
Técnicas de Cultivo de Célula/métodos , Células Dendríticas/inmunología , Inmunoterapia Adoptiva/métodos , Enfermedades Renales/inmunología , Linfocitos T Reguladores/inmunología , Antígenos CD4/metabolismo , Procesos de Crecimiento Celular , Separación Celular , Células Cultivadas , Citocinas/metabolismo , Citometría de Flujo , Antígenos HLA/inmunología , Humanos , Terapia de Inmunosupresión , Subunidad alfa del Receptor de Interleucina-2/metabolismo , Subunidad alfa del Receptor de Interleucina-7/metabolismo , Enfermedades Renales/terapia , Trasplante de Riñón , Guías de Práctica Clínica como Asunto , Tolerancia al Trasplante , Listas de Espera
5.
Scand J Immunol ; 77(2): 135-43, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23216075

RESUMEN

Congenital cytomegalovirus (CMV) infection is the most common congenital infection causing childhood morbidity. The pathogenetic mechanisms behind long-term sequelae are unclear, but long-standing viremia as a consequence of the inability to convert the virus to a latent state has been suggested to be involved. Whereas primary CMV infection in adults is typically rapidly controlled by the immune system, children have been shown to excrete virus for years. Here, we compare T cell responses in children with congenital CMV infection, children with postnatal CMV infection and adults with symptomatic primary CMV infection. The study groups included 24 children with congenital CMV infection, 19 children with postnatal CMV infection and eight adults with primary CMV infection. Among the infants with congenital CMV infection, 13 were symptomatic. T cell responses were determined by analysis of interferon gamma production after stimulation with CMV antigen. Our results show that whereas adults display high CMV-specific CD4 T cell responses in the initial phase of the infection, children younger than 2 years have low or undetectable responses that appear to increase with time. There were no differences between groups with regard to CD8 T cell function. In conclusion, inadequate CD 4 T cell function seems to be involved in the failure to get immune control of the CMV infection in children younger than 2 years of age with congenital as well as postnatal CMV infection.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Infecciones por Citomegalovirus/inmunología , Citomegalovirus/inmunología , Adolescente , Adulto , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/metabolismo , Preescolar , Epítopos de Linfocito T/inmunología , Femenino , Humanos , Lactante , Recién Nacido , Interferón gamma/biosíntesis , Recuento de Linfocitos , Masculino , Gemelos , Adulto Joven
6.
Diabetologia ; 55(7): 1985-94, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22538358

RESUMEN

AIMS/HYPOTHESIS: γ-Aminobutyric acid (GABA) is a signalling molecule in the interstitial space in pancreatic islets. We examined the expression and function of the GABA signalling system components in human pancreatic islets from normoglycaemic and type 2 diabetic individuals. METHODS: Expression of GABA signalling system components was studied by microarray, quantitative PCR analysis, immunohistochemistry and patch-clamp experiments on cells in intact islets. Hormone release was measured from intact islets. RESULTS: The GABA signalling system was compromised in islets from type 2 diabetic individuals, where the expression of the genes encoding the α1, α2, ß2 and ß3 GABA(A) channel subunits was downregulated. GABA originating within the islets evoked tonic currents in the cells. The currents were enhanced by pentobarbital and inhibited by the GABA(A) receptor antagonist, SR95531. The effects of SR95531 on hormone release revealed that activation of GABA(A) channels (GABA(A) receptors) decreased both insulin and glucagon secretion. The GABA(B) receptor antagonist, CPG55845, increased insulin release in islets (16.7 mmol/l glucose) from normoglycaemic and type 2 diabetic individuals. CONCLUSIONS/INTERPRETATION: Interstitial GABA activates GABA(A) channels and GABA(B) receptors and effectively modulates hormone release in islets from type 2 diabetic and normoglycaemic individuals.


Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Antagonistas del GABA/farmacología , Células Secretoras de Insulina/metabolismo , Piridazinas/farmacología , Receptores de GABA-B/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/genética , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Femenino , Homeostasis , Humanos , Inmunohistoquímica , Células Secretoras de Insulina/efectos de los fármacos , Masculino , Persona de Mediana Edad , Receptores de GABA-B/genética , Transducción de Señal/efectos de los fármacos , Ácido gamma-Aminobutírico/efectos de los fármacos , Ácido gamma-Aminobutírico/genética
7.
Diabetologia ; 55(12): 3273-83, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22983635

RESUMEN

AIMS/HYPOTHESIS: Virally induced inflammatory responses, beta cell destruction and release of beta cell autoantigens may lead to autoimmune reactions culminating in type 1 diabetes. Therefore, viral capability to induce beta cell death and the nature of virus-induced immune responses are among key determinants of diabetogenic viruses. We hypothesised that enterovirus infection induces a specific gene expression pattern that results in islet destruction and that such a host response pattern is not shared among all enterovirus infections but varies between virus strains. METHODS: The changes in global gene expression and secreted cytokine profiles induced by lytic or benign enterovirus infections were studied in primary human pancreatic islet using DNA microarrays and viral strains either isolated at the clinical onset of type 1 diabetes or capable of causing a diabetes-like condition in mice. RESULTS: The expression of pro-inflammatory cytokine genes (IL-1-α, IL-1-ß and TNF-α) that also mediate cytokine-induced beta cell dysfunction correlated with the lytic potential of a virus. Temporally increasing gene expression levels of double-stranded RNA recognition receptors, antiviral molecules, cytokines and chemokines were detected for all studied virus strains. Lytic coxsackievirus B5 (CBV-5)-DS infection also downregulated genes involved in glycolysis and insulin secretion. CONCLUSIONS/INTERPRETATION: The results suggest a distinct, virus-strain-specific, gene expression pattern leading to pancreatic islet destruction and pro-inflammatory effects after enterovirus infection. However, neither viral replication nor cytotoxic cytokine production alone are sufficient to induce necrotic cell death. More likely the combined effect of these and possibly cellular energy depletion lie behind the enterovirus-induced necrosis of islets.


Asunto(s)
Efecto Citopatogénico Viral/inmunología , Diabetes Mellitus Tipo 1/patología , Enterovirus Humano B/inmunología , Infecciones por Enterovirus/patología , Animales , Células Cultivadas , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/virología , Enterovirus Humano B/patogenicidad , Infecciones por Enterovirus/inmunología , Infecciones por Enterovirus/virología , Femenino , Regulación de la Expresión Génica , Humanos , Inmunidad Innata , Inmunohistoquímica , Inflamación , Interleucina-1alfa/inmunología , Interleucina-1beta/inmunología , Masculino , Ratones , Persona de Mediana Edad , Necrosis , Factor de Necrosis Tumoral alfa/inmunología
8.
J Exp Med ; 185(5): 885-92, 1997 Mar 03.
Artículo en Inglés | MEDLINE | ID: mdl-9120394

RESUMEN

Immunoglobulins (Ig), particularly IgE, are believed to be crucially involved in the pathogenesis of asthma and, equally, in allergic models of the disease. To validate this paradigm we examined homozygous mutant C57BL/6 mice, which are B cell deficient, lacking all Ig. Mice were immunized intraperitoneally with 10 micrograms ovalbumin (OVA) plus alum, followed by daily (day 14-20) 30 min exposures to OVA aerosol (OVA/OVA group). Three control groups were run: OVA intraperitoneally plus saline (SAL) aerosol (OVA/SAL group); saline intraperitoneally plus saline aerosol; saline intraperitoneally plus OVA aerosol (n = 6-7). Lung and large airway tissues obtained 24 h after the last OVA or SAL exposure were examined by light microscopy and transmission electron microscopy (TEM). The Ig-deficient mice receiving OVA/ OVA treatment had swollen and discolored lungs and exhibited marked eosinophilia both in large airway subepithelial tissue (49.2 +/- 12.0 cells/mm basement membrane [BM] versus OVA/ SAL control 1.2 +/- 0.3 cells/mm BM; P < 0.001), and perivascularly and peribronchially in the lung (49.3 +/- 9.0 cells/unit area versus OVA/SAL control 2.6 +/- 0.6 cells/unit area; P < 0.001). The eosinophilia extended to the regional lymph nodes. TEM confirmed the subepithelial and perivascular localization of eosinophils. Mucus cells in large airway epithelium increased from 1.5 +/- 0.8 (OVA/SAL mice) to 39.5 +/- 5.7 cells/mm BM in OVA/OVA treated mice (P < 0.001). OVA/SAL mice never differed from the other control groups. Corresponding experiments in wild-type mice (n = 6-7 in each group) showed qualitatively similar but less pronounced eosinophil and mucus cell changes. Macrophages and CD4+ T cells increased in lungs of all OVA/OVA-treated mice. Mast cell number did not differ but degranulation was detected only in OVA/OVA-treated wild-type mice. Immunization to OVA followed by OVA challenges thus cause eosinophil-rich inflammation in airways and lungs of mice without involvement of B cells and Ig.


Asunto(s)
Asma/inmunología , Linfocitos B/inmunología , Eosinófilos/inmunología , Inmunoglobulinas/deficiencia , Sistema Respiratorio/inmunología , Animales , Asma/patología , Modelos Animales de Enfermedad , Cadenas mu de Inmunoglobulina/genética , Pulmón/inmunología , Pulmón/patología , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/patología , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Tráquea/inmunología , Tráquea/patología
9.
J Exp Med ; 189(3): 553-62, 1999 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-9927517

RESUMEN

The earliest contact between antigen and the innate immune system is thought to direct the subsequent antigen-specific T cell response. We hypothesized that cells of the innate immune system, such as natural killer (NK) cells, NK1.1(+) T cells (NKT cells), and gamma/delta T cells, may regulate the development of allergic airway disease. We demonstrate here that depletion of NK1.1(+) cells (NK cells and NKT cells) before immunization inhibits pulmonary eosinophil and CD3(+) T cell infiltration as well as increased levels of interleukin (IL)-4, IL-5, and IL-12 in bronchoalveolar lavage fluid in a murine model of allergic asthma. Moreover, systemic allergen-specific immunoglobulin (Ig)E and IgG2a levels and the number of IL-4 and interferon gamma-producing splenic cells were diminished in mice depleted of NK1.1(+) cells before the priming regime. Depletion of NK1.1(+) cells during the challenge period only did not influence pulmonary eosinophilic inflammation. CD1d1 mutant mice, deficient in NKT cells but with normal NK cells, developed lung tissue eosinophilia and allergen-specific IgE levels not different from those observed in wild-type mice. Mice deficient in gamma/delta T cells showed a mild attenuation of lung tissue eosinophilia in this model. Taken together, these findings suggest a critical role of NK cells, but not of NKT cells, for the development of allergen-induced airway inflammation, and that this effect of NK cells is exerted during the immunization. If translatable to humans, these data suggest that NK cells may be critically important for deciding whether allergic eosinophilic airway disease will develop. These observations are also compatible with a pathogenic role for the increased NK cell activity observed in human asthma.


Asunto(s)
Alérgenos/inmunología , Asma/inmunología , Células Asesinas Naturales/inmunología , Eosinofilia Pulmonar/inmunología , Linfocitos T/inmunología , Animales , Antígenos , Antígenos Ly , Antígenos de Superficie , Asma/etiología , Líquido del Lavado Bronquioalveolar/inmunología , Citocinas/análisis , Lectinas Tipo C , Depleción Linfocítica , Masculino , Ratones , Ratones Endogámicos C57BL , Subfamilia B de Receptores Similares a Lectina de Células NK , Ovalbúmina/inmunología , Proteínas , Eosinofilia Pulmonar/etiología , Receptores de Antígenos de Linfocitos T gamma-delta , Bazo/citología , Bazo/inmunología , Factores de Tiempo , Vacunación
10.
Scand J Immunol ; 71(2): 83-90, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20384859

RESUMEN

A human islet transplant can cure patients with type 1 diabetes. A drawback of islet transplantation is the life-long immunosuppressive medication, often associated with severe side effects. Moreover, in spite of the immunosuppressive therapy, islets are lost in the majority of transplanted patients over time. An improved small animal model for studies on human islet allograft rejection mechanisms and the development of new measures for its prevention is clearly warranted. Here, we evaluated the potential of Balb/cRag2(-/-)gammac(-/-) mice carrying a human-like immune system (so-called humanized mice) as a tool for studies on the rejection of transplanted human islets. Human T cells from Balb/cRag2(-/-)gammac(-/-) mice, which as neonates had been transplanted with CD34(+) human cord blood haematopoietic stem cells (HIS mice), proliferated in response to allogeneic human dendritic cells, but failed to reject a human islet allograft transplanted to the renal subcapsular space as assessed by immunohistochemistry and analysis of human serum C-peptide levels. Histological analysis revealed that few if any T cells had migrated to the grafted tissue. These observations question the usefulness of the HIS mouse model for studies on human islet allograft rejection mechanisms and highlight the need for further improvements.


Asunto(s)
Modelos Animales de Enfermedad , Rechazo de Injerto/inmunología , Trasplante de Células Madre Hematopoyéticas/métodos , Trasplante de Islotes Pancreáticos/inmunología , Animales , Separación Celular , Proteínas de Unión al ADN/genética , Diabetes Mellitus Tipo 1/cirugía , Sangre Fetal , Citometría de Flujo , Humanos , Inmunohistoquímica , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Linfocitos T/inmunología , Trasplante Homólogo
11.
Diabetologia ; 52(7): 1352-62, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19415233

RESUMEN

AIMS/HYPOTHESIS: Optimising islet culture conditions may be one strategy for reducing islet loss prior to, and immediately after, islet transplantation. Liver X receptor (LXR) agonism has previously been shown to increase insulin release from pancreatic islets and reduce inflammation in leucocytes. Our aim was to investigate whether the synthetic LXR agonist GW3965 could modulate the inflammatory status of human pancreatic islets. METHODS: Levels of pro-inflammatory cytokines and tissue factor in isolated human islets were determined by TaqMan low density array and/or real-time quantitative RT-PCR (mRNA levels) and enzyme immunoassay (EIA) (protein levels). Islet viability was measured using intracellular ATP content, ADP/ATP ratio, mitochondrial dehydrogenase activity (XTT assay) and insulin secretion in a dynamic glucose-challenge model. Apoptosis was determined by EIA measurement of histone-DNA complexes present in cytoplasm and by assaying caspase-3/-7 activity. RESULTS: Treatment of LPS-stimulated human islets with the synthetic LXR agonist GW3965 (1 micromol/l) for 24 h reduced mRNA and protein levels of selected pro-inflammatory cytokines (IL-8, monocyte chemotactic protein-1 and tissue factor). Moreover, GW3965 had no adverse effect on insulin secretion, islet viability or apoptosis. No excess of lipid accumulation could be detected with the dosage and exposure time used. CONCLUSIONS/INTERPRETATION: LXR activation suppresses inflammation in human islets in vitro without adverse effects on islet viability. Short-term moderate activation of LXR prior to islet transplantation may represent a possible strategy for improving post-transplant islet survival.


Asunto(s)
Benzoatos/farmacología , Bencilaminas/farmacología , Proteínas de Unión al ADN/agonistas , Islotes Pancreáticos , Receptores Citoplasmáticos y Nucleares/agonistas , Tromboplastina/metabolismo , Adulto , Anciano , Antiinflamatorios/farmacología , Biomarcadores/metabolismo , Técnicas de Cultivo de Célula , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Colesterol/metabolismo , Proteínas de Unión al ADN/metabolismo , Femenino , Expresión Génica/efectos de los fármacos , Expresión Génica/fisiología , Homeostasis/efectos de los fármacos , Homeostasis/fisiología , Humanos , Insulina/metabolismo , Secreción de Insulina , Interleucina-8/genética , Interleucina-8/metabolismo , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/inmunología , Islotes Pancreáticos/metabolismo , Trasplante de Islotes Pancreáticos , Lipopolisacáridos/farmacología , Receptores X del Hígado , Masculino , Metilprednisolona/farmacología , Receptores Nucleares Huérfanos , Receptores Citoplasmáticos y Nucleares/metabolismo , Tromboplastina/genética , Donantes de Tejidos
12.
Am J Transplant ; 9(12): 2816-24, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19845588

RESUMEN

The fate of islets in clinical transplantation is unclear. To elude on this positron emission tomography combined with computed tomography (PET/CT) was performed for 60 min during islet transplantation in five patients receiving six transplants. A fraction of the islets (23%) were labeled with 18F-fluorodeoxyglucose ([(18)F]FDG) and carefully mixed with unlabeled islets just prior to intraportal transplantation. The peak radioactivity concentration in the liver was found at 19 min after start of islet infusion and corresponded to only 75% of what was expected, indicating that islets are lost during the transplantation procedure. No accumulation of radioactivity was found in the lungs. A nonphysiological peak of C-peptide was found in plasma during and immediately after transplantation in all subjects. Distribution in the liver was heterogeneous with wide variations in location and concentration. Islets found in areas with concentrations of >400 IEQ/cc liver tissue varied between 1% and 32% of the graft in different subjects. No side effects attributed to the PET/CT procedure were found. Clinical outcome in all patients was comparable to that previously observed indicating that the [(18)F]FDG labeling procedure did not harm the islets. The technique has potential to be used to assess approaches to enhance islet survival and engraftment in clinical transplantation.


Asunto(s)
Trasplante de Islotes Pancreáticos/métodos , Tomografía de Emisión de Positrones/métodos , Adulto , Anciano , Péptido C/sangre , Femenino , Fluorodesoxiglucosa F18 , Humanos , Inflamación/sangre , Hígado/diagnóstico por imagen , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Radiofármacos , Tomografía Computarizada por Rayos X
13.
Lab Anim ; 43(3): 249-54, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19246503

RESUMEN

Streptozotocin (STZ) given intravenously destroys pancreatic beta cells and is widely used in animal models to mimic type 1 diabetes. The effects of STZ on the clinical state of health and metabolism were studied in six high health certified domestic pigs weighing 19+/-1.3 kg at the start of the experiment. A single STZ dose of 150 mg/kg of body weight successfully induced hyperglycaemia and alterations in amino acid metabolism. Within 9 h after STZ administration, the blood glucose values fell from 5.4-7.5 mmol/L to 0.8-2.2 mmol/L. Hypoglycaemia was treated with 0.5 g glucose/kg body weight. In all pigs, hyperglycaemia was produced 24 h after STZ treatment, and 3 days after STZ injection, the glucose concentration was >25 mmol/L. Mean C-peptide concentration was 0.25+/-0.16 microg/L since 2 days after STZ injection until the end of the study. The serum concentration of the branched-chain amino acids (BCAA) increased four-fold, and alanine and taurine decreased by approximately 70% and 50%, respectively, after STZ treatment. All but one pig remained brisk and the physical examination was normal except for a retarded growth rate and a reduction of the skeletal muscle. At the end of the study, the pigs were moderately emaciated. Postmortem examination confirmed muscle wasting and a reduction of abdominal and subcutaneous fat. In conclusion, STZ-induced diabetes in pigs fulfils the requirements for a good animal model for type 1 diabetes with respect to clinical signs of the disease and alterations in the carbohydrate and amino acid metabolism.


Asunto(s)
Aminoácidos/metabolismo , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Alanina/sangre , Aminoácidos de Cadena Ramificada/sangre , Animales , Glucemia/análisis , Peso Corporal/efectos de los fármacos , Péptido C/sangre , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Tipo 1/inducido químicamente , Diabetes Mellitus Tipo 1/patología , Hiperglucemia , Insulina/metabolismo , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Porcinos , Taurina/sangre
15.
Am J Transplant ; 8(2): 458-62, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18093267

RESUMEN

A 7-year-old girl with severe hereditary pancreatitis underwent total pancreatectomy. A total of 160,000 islet equivalents (6400 islet/kg) were transplanted to the brachioradialis muscle of the right forearm. Her plasma C-peptide level was undetectable after pancreatectomy but increased to 1.37 ng/mL after 17 days; at this time point, her insulin requirement was 0.75 units of insulin/kg/day. At 5- and 27-months, her hemoglobin A1c (HbA1c) and insulin requirements were 4.5 and 5.3% and 0.3 and 0.18 units/kg/day, respectively. Basal and stimulated C-peptide levels were 0.67 +/- 0.07 and 3.36 +/- 1.37 ng/mL, respectively. Stimulated insulin levels were 30% higher in the islet-bearing arm compared to the contralateral arm after glucagon stimulation. After surgery and islet transplantation, the quality of life improved dramatically and she gained 8 kg of weight. In summary, a normal HbA1c, a low insulin requirement and the absence of recurrent hypoglycemia and the gradient of insulin between the arms indicate that the intramuscularly transplanted islets contribute to a long-term clinically significant metabolic control.


Asunto(s)
Trasplante de Islotes Pancreáticos/métodos , Pancreatectomía , Pancreatitis/cirugía , Trasplante Autólogo/métodos , Niño , Estudios de Seguimiento , Hemoglobina Glucada/análisis , Humanos , Músculo Esquelético , Pancreatitis/genética , Factores de Tiempo , Resultado del Tratamiento
16.
Cell Transplant ; 17(12): 1305-13, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-19364068

RESUMEN

A central step within the human islet isolation process is the separation of islets from contaminating exocrine tissue utilizing linear, continuous density gradients manufactured by means of manually controlled standard gradient makers (SGM). The present study was performed to develop a closed, automated purification system (APS) that customizes density gradient profiles aiming to standardize and optimize human islet purification. Digested human pancreata were pooled, split evenly, and incubated in UW solution according to our standard protocol (n = 11). Continuous density gradient centrifugation was performed in parallel in two refrigerated COBE 2991 cell separators loaded with light (1.076 g/ml) and heavy (1.097 g/ml) Ficoll utilizing either an SGM or two computer-controlled pumps connected to Ficoll-containing bags. Quality control included islet equivalent (IE) yield, purity, in vitro function, and islet cytokine expression. Gradient profiles demonstrated that the APS readily customizes linear and nonlinear gradients. In comparison to the SGM, the APS recovered a higher percentage of the expected volume of continuous gradients (90.0 +/- 1.1% vs. 98.2 +/- 2.0%, p < 0.05). Islet yield (120,468 +/- 15,970 vs. 114,570 +/- 15,313 IE, NS) and purity (51.7 +/- 4.8% vs. 54.4 +/- 4.9%, NS) were nearly identical utilizing the SGM or APS. Decreased MCP-1, IL-6, and IL-8 expression indicated that APS-purified islets were possibly exposed to less proinflammatory stress. Compared to standard procedures, similar success and gentle continuous density gradient separation of human islets is feasible utilizing the APS. The APS facilitates the standardization of this complex procedure according to cGMP standards.


Asunto(s)
Islotes Pancreáticos/citología , Adulto , Automatización , Muerte Encefálica , Separación Celular/métodos , Centrifugación por Gradiente de Densidad , Diabetes Mellitus Tipo 1/cirugía , Femenino , Humanos , Trasplante de Islotes Pancreáticos/métodos , Masculino , Persona de Mediana Edad , Donantes de Tejidos
17.
Diabetes Obes Metab ; 10 Suppl 4: 119-27, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18834439

RESUMEN

Basement membranes (BMs) are an important part of the physiological microenvironment of pancreatic islet cells. In mouse islets, beta-cells interact directly with BMs of capillary endothelial cells. We have shown that in the human islets, the capillaries are surrounded by a double BM both in foetal and adult tissues. The endocrine islet cells are facing a BM that is separate from the endothelia. Laminins are the functionally most important component of BMs. The only laminin isoform present in the human endocrine islet BM is laminin-511 (previously known as laminin 10). The islet cells facing this BM have a strong and polarized expression of Lutheran glycoprotein, which is a well-known receptor for the laminin alpha 5 chain. Dispersed human islet cells adhere to purified human laminin-511 and the binding is equally effectively blocked by a soluble form of Lutheran as by antibody against integrin beta1. Our results reveal unique features of the BM structure of human islets, different from rodents. This information has potentially important implications for the generation of an optimal microenvironment for beta-cell function, proliferation and differentiation.


Asunto(s)
Membrana Basal/fisiología , Diferenciación Celular/fisiología , Matriz Extracelular/fisiología , Células Secretoras de Insulina/fisiología , Islotes Pancreáticos/fisiopatología , Laminina/fisiología , Páncreas/fisiopatología , Animales , Membrana Basal/embriología , Membrana Basal/metabolismo , Ciclo Celular/fisiología , Matriz Extracelular/metabolismo , Humanos , Islotes Pancreáticos/embriología , Islotes Pancreáticos/metabolismo , Laminina/metabolismo , Sistema del Grupo Sanguíneo Lutheran/metabolismo , Ratones , Páncreas/embriología , Isoformas de Proteínas/metabolismo , Receptores de Laminina/metabolismo
18.
Transplant Proc ; 40(2): 370-1, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18374071

RESUMEN

OBJECTIVE: The utilization of purified enzyme blends consisting of collagenase class I (CI) and II (CII) and neutral protease is an essential step for clinical islet isolation. Previous studies suggested that the use of enzyme lots containing degraded CI reduced islet release from human pancreata. The present study sought to assess the effect of degraded collagenase on islet function in vitro and posttransplantation. MATERIALS AND METHODS: Crude collagenase was chromatographically separated into CI, CII, and a mixture of degraded CI and CII isomers. Subsequently, classes were recombined to obtain a CII/CI ratio of 0.5. Rat islets were isolated utilizing neutral protease and 20 units of recombined collagenase containing either intact (Ci) or degraded isomers (Cd). RESULTS: Digestion time was reduced utilizing Cd (P < .001). The highest islet yield and lowest islet fragmentation were obtained with Ci (P < .01). Utilization of Cd corresponded to a reduction in viability and in vitro function (NS). Islet transplantation reversed hyperglycemia in diabetic nude mice, but revealed an absence of weight gain in recipients receiving islets isolated using Cd (P < .01). CONCLUSION: This study suggested that islet function posttransplantation is affected by degraded collagenase isomers. This finding has to be considered for the purification process of collagenase.


Asunto(s)
Supervivencia Celular , Colagenasas , Trasplante de Islotes Pancreáticos/fisiología , Islotes Pancreáticos/citología , Metaloproteinasa 8 de la Matriz , Recolección de Tejidos y Órganos/métodos , Animales , Supervivencia Celular/efectos de los fármacos , Colagenasas/farmacología , Islotes Pancreáticos/efectos de los fármacos , Metaloproteinasa 8 de la Matriz/farmacología , Ratas , Resultado del Tratamiento
19.
Transplant Proc ; 40(2): 393-4, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18374079

RESUMEN

OBJECTIVE: Pancreas shipment is frequently associated with prolonged ischemia deteriorating islet graft function. The strategy to prevent ischemic damage utilizing perfluorodecalin (PFD) for human pancreas oxygenation does not seem to improve isolation outcome. The present study investigated the efficiency of perfluorohexyloctane (F6H8), a hyperoxygen carrier characterized by low specific density (1.33 g/cm3) and lipophilic qualities, to facilitate islet isolation from long-term stored rat pancreata. MATERIALS AND METHODS: Prior to islet isolation, pancreata were intraductally flushed in situ with Kyoto solution (KS) and stored for 24 hours in KS, oxygenated PFD, or F6H8. RESULTS: Islet isolation performed after 24-hour storage in KS failed completely. The intrapancreatic pO2 in PFD- and F6H8-incubated pancreata was almost the same. In correspondence, the ATP content and viability of isolated islets were similar as well. In contrast, islet yield and in vitro function were significantly reduced after storage in PFD compared with F6H8. CONCLUSION: This study suggested that islet isolation performed after long-term pancreas preservation can be significantly improved utilizing semifluorinated alkanes as oxygen carriers.


Asunto(s)
Islotes Pancreáticos/citología , Páncreas/citología , Animales , Sustitutos Sanguíneos/farmacología , Separación Celular/métodos , Fluorocarburos/farmacología , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/fisiología , Preservación de Órganos/métodos , Soluciones Preservantes de Órganos , Consumo de Oxígeno , Ratas , Ratas Endogámicas Lew
20.
J Clin Invest ; 93(3): 1113-9, 1994 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8132751

RESUMEN

Allogeneic mouse islets or xenogeneic rat islets, or fetal porcine islets were implanted under the renal capsule of C57BL/6 mice either alone or carefully mixed with syngeneic islets. With this experimental model the syngeneic islets, although not rejected themselves, are exposed to cytokines and inflammatory mediators released during either allograft or xenograft rejection. No differences in insulin content could be observed between mixed islet grafts and pure syngeneic islet grafts 6 wk after transplantation. Neither was there any morphological evidence of a non-specific destruction of syngeneic islets. These findings suggest that the mechanisms of both allograft and xenograft rejections are highly specific. The hormone release from the mixed syngeneic-allogeneic grafts was similar to that from pure syngeneic islet grafts. In contrast, a pronounced impairment of both the first and second phases of insulin release was observed 2 wk after implantation in mixed syngeneic-xenogeneic islet grafts. When perfusing the mixed islet graft after completed rejection of the concordant xenogeneic rat islets (6 wk after implantation), the insulin release from the remaining syngeneic mouse islets was identical to that of control grafts. However, syngeneic mouse islets exposed to the rejection mechanism of the discordant xenogenic pig islet-like cell clusters did not attain a complete functional recovery.


Asunto(s)
Rechazo de Injerto , Trasplante de Islotes Pancreáticos , Trasplante Heterólogo , Animales , ADN/análisis , Femenino , Insulina/análisis , Insulina/metabolismo , Secreción de Insulina , Interleucina-1/metabolismo , Islotes Pancreáticos/química , Islotes Pancreáticos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Perfusión , Ratas , Ratas Sprague-Dawley , Trasplante Homólogo , Trasplante Isogénico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA